Drug Profile
CSL 730
Alternative Names: CSL 730 rFc Multimer; CSL-730; M 230; Recombinant trivalent human IgG1 Fc multimerLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Momenta Pharmaceuticals
- Developer CSL Behring; Momenta Pharmaceuticals
- Class Antirheumatics; Immunoglobulins; Recombinant proteins; Skin disorder therapies
- Mechanism of Action Fc receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
- Discontinued Epidermolysis bullosa; Idiopathic thrombocytopenic purpura
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in United Kingdom (SC, Infusion)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in United Kingdom (SC, Injection)
- 28 Mar 2023 CSL Behring terminates a phase-I clinical trials in Autoimmune disorders (In volunteers) in United Kingdom (SC, Injection) (NCT04446000)